BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26317650)

  • 1. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
    Liao MY; Lai JK; Kuo MY; Lu RM; Lin CW; Cheng PC; Liang KH; Wu HC
    Oncotarget; 2015 Sep; 6(28):24947-68. PubMed ID: 26317650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between ganglioside expression and anti-cancer effects of the monoclonal antibody against epithelial cell adhesion molecule in colon cancer.
    Kwak DH; Ryu JS; Kim CH; Ko K; Ma JY; Hwang KA; Choo YK
    Exp Mol Med; 2011 Dec; 43(12):693-701. PubMed ID: 22033101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
    Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus.
    Kawashima R; Abei M; Fukuda K; Nakamura K; Murata T; Wakayama M; Seo E; Hasegawa N; Mizuguchi H; Obata Y; Hyodo I; Hamada H; Yokoyama KK
    Int J Cancer; 2011 Sep; 129(5):1244-53. PubMed ID: 21710497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer.
    Liao MY; Kuo MY; Lu TY; Wang YP; Wu HC
    Int J Oncol; 2015 Apr; 46(4):1788-800. PubMed ID: 25652097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA.
    Hao H; Zhen Y; Wang Z; Chen F; Xie X
    Cell Biol Int; 2013 Aug; 37(8):860-4. PubMed ID: 23576466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.
    Yamashita T; Honda M; Nio K; Nakamoto Y; Yamashita T; Takamura H; Tani T; Zen Y; Kaneko S
    Cancer Res; 2010 Jun; 70(11):4687-97. PubMed ID: 20484035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells.
    Liang KH; Tso HC; Hung SH; Kuan II; Lai JK; Ke FY; Chuang YT; Liu IJ; Wang YP; Chen RH; Wu HC
    Cancer Lett; 2018 Oct; 433():165-175. PubMed ID: 29981429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody.
    Andratschke M; Gildehaus FJ; Johannson V; Schmitt B; Mack B; Reisbach G; Lang S; Lindhofer H; Zeidler R; Wollenberg B; Luebbers CW
    Anticancer Res; 2007; 27(1A):431-6. PubMed ID: 17352264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EpCAM-targeted therapy for human hepatocellular carcinoma.
    Ogawa K; Tanaka S; Matsumura S; Murakata A; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Tanabe M; Arii S
    Ann Surg Oncol; 2014 Apr; 21(4):1314-22. PubMed ID: 24370904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
    Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
    PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes.
    Heine M; Freund B; Nielsen P; Jung C; Reimer R; Hohenberg H; Zangemeister-Wittke U; Wester HJ; Lüers GH; Schumacher U
    PLoS One; 2012; 7(5):e36258. PubMed ID: 22590529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
    Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
    Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
    Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.